Recent events
Recent events tied to this brand in public sources.
Back to profile7 entries
2022
COMPASS Pathways reports 2021 financial results
COMPASS Pathways reported financial results for the fourth quarter and full year 2021, including a full-year net loss of $71.7 million and cash and cash equivalents of $273.2 million at year-end.
2021
COMPASS Pathways acquires psychedelic-compounds IP portfolio
COMPASS Pathways announced that it had acquired an intellectual-property portfolio covering patent applications for psychedelic and empathogenic substances, developed with MiHKAL founder Matthias Grill.
2021
COMPASS Pathways prices public offering
COMPASS Pathways announced the pricing of a public offering of 4,000,000 American Depositary Shares at $36.00 per share, for total gross proceeds of $144.0 million. The offering was expected to close on or about May 4, 2021.
2021
COMPASS Pathways appoints Wayne J Riley to its board
COMPASS Pathways announced that it appointed Wayne J Riley MD to its Board of Directors.
2021
COMPASS expands Discovery Center research collaborations
COMPASS Pathways announced an expansion of its Discovery Center through collaborations with laboratories at UC San Diego School of Medicine and Medical College of Wisconsin. The collaborating researchers and their teams will work on developing new psychedelic compounds; COMPASS will be the exclusive licensee for compounds generated.
2020
COMPASS Pathways announces IPO pricing
COMPASS Pathways announced pricing for its upsized U.S. initial public offering: 7,500,000 American Depositary Shares at $17.00 each, for total gross proceeds of $127.5 million. Trading and closing were described as expected future steps.
2020
Compass Pathways files for U.S. IPO
Compass Pathways filed for an initial public offering and said it plans to list its American depositary shares on the Nasdaq under the ticker CMPS.